Equillium grants Ono an option to purchase rights to itolizumab
Equillium to receive an upfront payment of approximately $26.0M (¥3.5B); eligible to receive up to approximately $138.5M (¥18.7B) in option exercise and milestone payments
Ono to fund Equillium’s continued research and development of itolizumab during the exercise period
Conference call and webcast today at 8:30 a.m. ET
Management will host a conference call to discuss the option and asset purchase agreement with Ono Pharmaceutical Co., Ltd. for analysts and institutional investors, at 8:30 a.m. ET today, December 6, 2022. To access the call, please dial (888) 350-3846 or (646) 960-0251 and, if needed, provide confirmation number 8770084. A live webcast of the call will also be available on the company’s Investor Relations page at www.equilliumbio.com/investors/events-and-presentations/default.aspx. The webcast will be archived for 180 days.
https://finance.yahoo.com/news/equillium-ono-pharmaceutical-announce-exclusive-120000241.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.